Assenagon Asset Management S.A. Aravive, Inc. Transaction History

Assenagon Asset Management S.A.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 25, 2023	SELL	$1.25 - $1.92 $225,141 - $345,816	-180,113 Reduced 89.85%	20,340 $25,000
Q1 2023 Apr 18, 2023	BUY	$1.29 - $2.46 $258,584 - $493,114	200,453 New	200,453 $400,000
Q2 2022 Jul 27, 2022	BUY	$0.93 - $1.9 $42,805 - $87,451	46,027 New	46,027 $45,000
Q2 2021 Jul 15, 2021	SELL	$4.65 - $6.42 $62,198 - $85,873	-13,376 Closed	0 $0
Q1 2021 Apr 26, 2021	SELL	$5.11 - $9.24 $81 - $147	-16 Reduced 0.12%	13,376 $88,000
Q4 2020 Feb 01, 2021	SELL	$4.36 - $6.51 $331,394 - $494,812	-76,008 Reduced 85.02%	13,392 $0
Q3 2020 Oct 07, 2020	BUY	$4.7 - $12.06 $420,180 - $1.08 Million	89,400 New	89,400 $420,000

28.1K

Ticker ARAV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,518,300
Description
Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of pl...

Get notified when there are updates to the investment portfolio of Assenagon Asset Management S.A., based on Form 13F filings with the SEC.

Stay updated on Assenagon Asset Management S.A. with notifications on news.